285 related articles for article (PubMed ID: 30287151)
1. Vitamin D protects against diabetic nephropathy: Evidence-based effectiveness and mechanism.
Hu X; Liu W; Yan Y; Liu H; Huang Q; Xiao Y; Gong Z; Du J
Eur J Pharmacol; 2019 Feb; 845():91-98. PubMed ID: 30287151
[TBL] [Abstract][Full Text] [Related]
2. Vitamin D protection from rat diabetic nephropathy is partly mediated through Klotho expression and renin-angiotensin inhibition.
Eltablawy N; Ashour H; Rashed LA; Hamza WM
Arch Physiol Biochem; 2018 Dec; 124(5):461-467. PubMed ID: 29308676
[TBL] [Abstract][Full Text] [Related]
3. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.
Song JH; Lee SW; Suh JH; Kim ES; Hong SB; Kim KA; Kim MJ
Clin Nephrol; 2003 Nov; 60(5):318-26. PubMed ID: 14640237
[TBL] [Abstract][Full Text] [Related]
4. ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1.
Amann B; Tinzmann R; Angelkort B
Diabetes Care; 2003 Aug; 26(8):2421-5. PubMed ID: 12882873
[TBL] [Abstract][Full Text] [Related]
5. Vitamin D and diabetic nephropathy.
Li YC
Curr Diab Rep; 2008 Dec; 8(6):464-9. PubMed ID: 18990303
[TBL] [Abstract][Full Text] [Related]
6. Renin Angiotensin Aldosterone System (RAAS): its biology and drug targets for treating diabetic nephropathy.
Zain M; Awan FR
Pak J Pharm Sci; 2014 Sep; 27(5):1379-91. PubMed ID: 25176370
[TBL] [Abstract][Full Text] [Related]
7. Vitamin D improves diabetic nephropathy in rats by inhibiting renin and relieving oxidative stress.
Deng X; Cheng J; Shen M
J Endocrinol Invest; 2016 Jun; 39(6):657-66. PubMed ID: 26691308
[TBL] [Abstract][Full Text] [Related]
8. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
[TBL] [Abstract][Full Text] [Related]
9. High levels of circulating TNFR1 increase the risk of all-cause mortality and progression of renal disease in type 2 diabetic nephropathy.
Fernández-Juárez G; Villacorta Perez J; Luño Fernández JL; Martinez-Martinez E; Cachofeiro V; Barrio Lucia V; Tato Ribera AM; Mendez Abreu A; Cordon A; Oliva Dominguez JA; Praga Terente M
Nephrology (Carlton); 2017 May; 22(5):354-360. PubMed ID: 27003829
[TBL] [Abstract][Full Text] [Related]
10. Vitamin D receptor and its protective role in diabetic nephropathy.
Guan X; Yang H; Zhang W; Wang H; Liao L
Chin Med J (Engl); 2014; 127(2):365-9. PubMed ID: 24438630
[TBL] [Abstract][Full Text] [Related]
11. Vitamin D and proteinuria: a critical review of molecular bases and clinical experience.
Pérez-Gómez MV; Ortiz-Arduán A; Lorenzo-Sellares V
Nefrologia; 2013; 33(5):716-26. PubMed ID: 24089164
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological Management of Diabetic Nephropathy.
Papademetriou V; Alataki S; Stavropoulos K; Papadopoulos C; Bakogiannis K; Tsioufis K
Curr Vasc Pharmacol; 2020; 18(2):139-147. PubMed ID: 30961500
[TBL] [Abstract][Full Text] [Related]
13. NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy.
Mezzano S; Aros C; Droguett A; Burgos ME; Ardiles L; Flores C; Schneider H; Ruiz-Ortega M; Egido J
Nephrol Dial Transplant; 2004 Oct; 19(10):2505-12. PubMed ID: 15280531
[TBL] [Abstract][Full Text] [Related]
14. Dual renin-angiotensin system blockade for nephroprotection.
Ruggenenti P
Nephrol Ther; 2017 Apr; 13 Suppl 1():S43-S45. PubMed ID: 28577742
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase.
Zhang Z; Zhang Y; Ning G; Deb DK; Kong J; Li YC
Proc Natl Acad Sci U S A; 2008 Oct; 105(41):15896-901. PubMed ID: 18838678
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis: the efficacy and safety of combined treatment with ARB and ACEI on diabetic nephropathy.
Ren F; Tang L; Cai Y; Yuan X; Huang W; Luo L; Zhou J; Zheng Y
Ren Fail; 2015 May; 37(4):548-61. PubMed ID: 25707526
[TBL] [Abstract][Full Text] [Related]
17. Dual Renin-Angiotensin-Aldosterone System Inhibition for the Treatment of Diabetic Kidney Disease: Adverse Effects and Unfulfilled Promise.
El-Haddad B; Reule S; Drawz PE
Curr Diab Rep; 2015 Oct; 15(10):70. PubMed ID: 26275442
[TBL] [Abstract][Full Text] [Related]
18. ACEI and ARB combination therapy in patients with macroalbuminuric diabetic nephropathy and low socioeconomic level: a double-blind randomized clinical trial.
Titan SM; M Vieira J; Dominguez WV; Barros RT; Zatz R
Clin Nephrol; 2011 Oct; 76(4):273-83. PubMed ID: 21955862
[TBL] [Abstract][Full Text] [Related]
19. Renoprotective Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Diabetic Patients with Proteinuria.
Hsu FY; Lin FJ; Ou HT; Huang SH; Wang CC
Kidney Blood Press Res; 2017; 42(2):358-368. PubMed ID: 28618426
[TBL] [Abstract][Full Text] [Related]
20. Renin-angiotensin system activation and interstitial inflammation in human diabetic nephropathy.
Mezzano S; Droguett A; Burgos ME; Ardiles LG; Flores CA; Aros CA; Caorsi I; Vío CP; Ruiz-Ortega M; Egido J
Kidney Int Suppl; 2003 Oct; (86):S64-70. PubMed ID: 12969130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
